文献速递浆细胞疾病

免疫适应性与复发/难治性多发性骨髓瘤患者对teclistamab治疗反应的相关性:MajesTEC-1研究

Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study.
PubMed 文献 · Blood · 2024-01-01

基于关键性1/2期MajesTEC-1研究,纳入接受1.5 mg/kg teclistamab治疗的复发/难治性多发性骨髓瘤患者165例,分析基线免疫特征与临床反应的关系。结果显示,外周血基线总T细胞计数较高、调节性T细胞比例较低、表达共抑制受体(CD38、PD-1、PD-1/TIM-3)的T细胞及可溶性BCMA水平较低者,临床反应更好;无反应者免疫特征提示免疫抑制和T细胞功能障碍。

要点

  • 基线外周血总T细胞计数较高与teclistamab更好的临床结局相关。
  • 缓解者(部分缓解及以上)较无缓解者调节性T细胞比例更低。
  • 基线骨髓BCMA表达频率及BCMA受体密度与临床反应无关。

核心结论

  • teclistamab的总体反应与基线免疫适应性相关。
  • 无反应者具有提示免疫抑制和T细胞功能障碍的免疫特征。

研究设计与样本

  • 研究为关键性1/2期MajesTEC-1研究,聚焦接受1.5 mg/kg teclistamab治疗的复发/难治性多发性骨髓瘤患者165例。
  • 外周血样本于筛选时采集,骨髓样本于筛选时和第3周期采集。

主要发现

  • 外周血基线总T细胞计数较高与teclistamab更好的临床结局相关。
  • 缓解者(部分缓解或更好)较无缓解者具有更低比例的免疫抑制性调节性T细胞、表达共抑制受体(CD38、PD-1和PD-1/TIM-3)的T细胞及可溶性BCMA,且T细胞特征提示更强的细胞溶解潜力。
  • 基线骨髓BCMA表达频率及BCMA受体密度均与teclistamab临床反应无关。
  • 表达耗竭标志物的T细胞频率较低和免疫抑制性调节性T细胞频率较低的患者,无进展生存期改善。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Teclistamab, an off-the-shelf B-cell maturation antigen (BCMA) × CD3 bispecific antibody that mediates T-cell activation and subsequent lysis of BCMA-expressing myeloma cells, is approved for the treatment of patients with relapsed/refractory multiple myeloma (R/RMM). As a T-cell redirection therapy, clinical outcomes with teclistamab may be influenced by patient immune fitness and tumor antigen expression. We correlated tumor characteristics and baseline immune profiles with clinical response and disease burden in patients with R/RMM from the pivotal phase 1/2 MajesTEC-1 study, focusing on patients treated with 1.5 mg/kg of teclistamab (N = 165). Peripheral blood samples were collected at screening, and bone marrow samples were collected at screening and cycle 3. Better clinical outcomes to teclistamab correlated with higher baseline total T-cell counts in the periphery. In addition, responders (partial response or better) had a lower proportion of immunosuppressive regulatory T cells (Tregs), T cells expressing coinhibitory receptors (CD38, PD-1, and PD-1/TIM-3), and soluble BCMA and a T-cell profile suggestive of a more cytolytic potential, compared with nonresponders. Neither frequency of baseline bone marrow BCMA expression nor BCMA-receptor density was associated with clinical response to teclistamab. Improved progression-free survival was observed in patients with a lower frequency of T cells expressing exhaustion markers and immunosuppressive Tregs. Overall, response to teclistamab was associated with baseline immune fitness; nonresponders had immune profiles suggestive of immune suppression and T-cell dysfunction. These findings illustrate the importance of the contribution of the immune landscape to T-cell redirection therapy response. This trial was registered at www.ClinicalTrials.gov as #NCT03145181/NCT04557098.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Cortes-Selva D, Perova T, Skerget S, et al. Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study. Blood. 2024. PMID: 38657201. doi:10.1182/blood.2023022823

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。